Concepedia

Rik J. Verheijden

RJ

Statistics

Publications

13

Citations

396

H-Index

12

Active since

2020

Affiliations

University Medical Center Utrecht(Current)

Utrecht University

Maastricht University Medical Centre

Erasmus University Rotterdam

Radboud University Medical Center

Rik J. Verheijden is an author at University Medical Center Utrecht specializing in immunosuppression, immunotherapy, and tumor microenvironment.

ORCID

Top concepts

Publications per year

2020–2025

13

Publications

13

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Olivier J. van Not, Rik J. Verheijden, Alfonsus Johannes Maria van den Eertwegh et al. · JAMA Oncology · 2022 · 99 citations · Full text

Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials

Rik J. Verheijden, Jolien S. de Groot, Babs O. Fabriek et al. · Journal of Clinical Oncology · 2024 · 72 citations

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Rik J. Verheijden, F.H. Burgers, Josephine C Janssen et al. · European Journal of Cancer · 2024 · 44 citations · Full text

, , +10

Frailty and checkpoint inhibitor toxicity in older patients with melanoma

Cheryl P. Bruijnen, José J. Koldenhof, Rik J. Verheijden et al. · Cancer · 2022 · 37 citations · Full text

Physical activity and checkpoint inhibition: association with toxicity and survival

Rik J. Verheijden, Anna Cabané Ballester, Karel C Smit et al. · JNCI Journal of the National Cancer Institute · 2023 · 24 citations · Full text

1–5 of 13